Abstract

BackgroundNuclear receptors are modulators of fibroblast activation which leads to tissue fibrosis, the hallmark of systemic sclerosis (SSc). Anti-fibrotic properties of rosiglitazone, a PPAR-γ agonist, have been reported previously, however...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call